chrisvoncsefalvay/vaers-outcomes huggingface dataset:
for 3 days had burning at site of injection, parathesias, numbness of hands and feet, blotchy red rash, head and neck. Serum sickness considered, treated with Prednisone.  11/23/2009 DC summary hospital records, neurology consult received. Service dates 10/2709 to 10/30/09. Assessment: Sensory polyneuropathy likely due to diabetes. Guillain Barre syndrome ruled out. Patient c/o burning, numbness. Numbness bilateral, pain in legs, weak in legs, off balance, staggering, red in face, sweats, and flutters in chest. Sore throat, indigestion, nausea, stomach problem.
Left arm pain after vaccine in 3/2023.  Upper arm pain is constant with forearm pain with hand movement.
Fever, cold chills, cold sweats, nausea and fatigue. Aches as in like my bones feel like they hurt especially around my joints.
warm; 6 inches long and 3 inches wide; raised in few spots/ 4inches long and 3 inches wide; red; A spontaneous report  was received from a consumer concerning a 77-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events red/Erythema, warm/Feeling hot, 6 inches long and 3 inches wide/Rash papular , was there for 2 nights after i noticed, came back again, raised in few spots, 4inches long and 3 inches wide/Rash erythematous.  The patient's medical history was not provided. Concomitant medications reported were levothyroxine, Paroxetine, Lorazepam  for drug use for unknown indication.  On 28 Jan 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: Lot# 025L20A) via unknown route for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the event(s) red, warm, 6 inches long and 3 inches wide, was there for 2 nights after I noticed, came back again, raised in few spots, 4inches long and 3 inches wide.It cleared up again.   Treatment information was not provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), red, warm, 6 inches long and 3 inches wide was there for 2 nights after i noticed, came back again, raised in few spots, 4inches long and 3 inches wide was unknown.
Right arm of patient where she received the pneumovax 23 showing erythema and swelling of the lower arm near elbow. No redness or swelling at the injection site. Per patient, the swelling has gone down in the past 2 days.  I advised patient to keep monitoring the symptoms and see her primary care provider. I will also check with patient in the next couple of days to monitor her symptoms.
Patient was given Moderna Monovalent Booster and patient needed Moderna Bivalent Booster.
A common reaction of ill feeling, slight fever and muscle aches occurred the following day. By the evening pain in the upper left abdominal quadrant. The following day, pain increased whenever force was exerted (cough, use of muscles near spleen ect). Pain and stiffness intensifying as the day goes on.
This case was reported by a consumer via other and described the occurrence of back pain in a male patient who received SHINGRIX for prophylaxis. On 19th July 2018, the patient received SHINGRIX. On 21st July 2018, 2 days after receiving SHINGRIX, the patient experienced back pain. On an unknown date, the outcome of the back pain was unknown. It was unknown if the reporter considered the back pain to be related to SHINGRIX. Additional details were reported as follows: This case was reported by a pharmacy via a pharmacy claims management company. The age at vaccination was not reported. The customer received a SHINGRIX vaccine and 2 days later he sustained severe lower back pain. He had been to the physician and had no relief.
Flu-like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms). At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms) had resolved.            No concomitant medications were provided. Treatment information was not provided.  Patient stated that flu-like symptoms which she experienced post second dose was more worse than post the first dose. However, she was feeling fine now.   This case was linked to MOD-2021-020927 (Patient Link).
BP spikes to 164 at night. Still high at night. Taking extra meds for it. Continued nausea, some dizziness, burping, prickly nerve endings with cold sensation. Headache.
Red at injection site 3x2 inches; Swollen at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Red at injection site 3x2 inches) and VACCINATION SITE SWELLING (Swollen at injection site) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 07K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Red at injection site 3x2 inches) and VACCINATION SITE SWELLING (Swollen at injection site). At the time of the report, VACCINATION SITE ERYTHEMA (Red at injection site 3x2 inches) and VACCINATION SITE SWELLING (Swollen at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  Treatment medications was not provided by reporter.   This case was linked to MOD-2021-254082 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: Follow up received on 16-APR-2021 and patient's address details were updated. On 12-Jul-2021: Follow up received on 12 Jul 2021 included updated event outcome.
pt noted that he stated experiencing red spots all over his arms, legs, and trunk the evening following the vaccination with no other changes to his regimen or activities. Pt reports mild itchiness.
I would say elevated blood pressure revealed January 2022 at a routine dental visit, subsequent visits to other providers also revealed elevated blood pressure. My most recent visit a healthcare provider addition of Spironolactone to Diovan may have resolved the problem.
Information has been received from a registered nurse (R.N.) concerning an approximately 9-year-old male who on 04-SEP-1997 was vaccinated with a dose of Varivax (Oka/Merck) (lot# 623130/0568E). Subsequently, on an unspecified date, the patient developed a generalized rash of 50-200 lesions. He was seen by a physician but no hospitalization was involved. No outcome was reported. Additional information has been received on 05-JUL-2006 from an unspecified woman who indicated that no further information is available on this patient.
Received a dose more than 30 days in the fridge; Received a dose more than 30 days in the fridge; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received a dose more than 30 days in the fridge) and PRODUCT STORAGE ERROR (Received a dose more than 30 days in the fridge) in a 75-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003F21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received a dose more than 30 days in the fridge) and PRODUCT STORAGE ERROR (Received a dose more than 30 days in the fridge). On 01-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Received a dose more than 30 days in the fridge) and PRODUCT STORAGE ERROR (Received a dose more than 30 days in the fridge) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant information was reported. No treatment information was reported.
Pt was admitted with signs and symptoms of Guillain-Barre Syndrome. Pt presented with bilateral and symmetrical limb weakness, and deep tendon reflexes were decreased. Pt was treated with IVIG.
I did not have an adverse reaction to the vaccine. I was thirteen weeks pregnant at the time I tested positive for COVID-19 on 01/09/2023. I contacted my doctor, and they recommended Tylenol and compression socks. I was very fatigued, and I had a fever. All my symptoms cleared up within two weeks.
I had pain in my neck right away, then started to have swelling in my throat. I took Benderyl, and that helped. In the following days had a fever, body aches, chest pain, and difficulty breathing. I had to go to the ER in city. They placed me on a Predisone and inhalers.  I continued to have chest pain and a cough. I went to the Cardiologist to work up due to chest pain. I did a stress test, that was ok. I was told that I had an inflammatory response to the vaccine and followed up with my PCP and would recommend me on inhalers. I am now taking inhaled steroids and bronchodilators. I still have to cough up large amounts of thick mucus and still have chest pain, especially in the right lung.
17 year old patient received the vaccine; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient received the vaccine) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Asthma.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient received the vaccine). On 26-Feb-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old patient received the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Relevant concomitant medication included inhaler for asthma. No treatment medications were provided   Most recent FOLLOW-UP information incorporated above includes: On 05-Apr-2021: Additional information received and contains medical history and concomitant medication.
Upon injection my arms and legs became weak.  A half hour later I was nauseous.  Both symptoms resolved after 1.5 hrs after injection. 2) Four days later I developed a lump under my arm pit in my lymph node on the same arm as the injection (L).  Lump resolved after a week.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 37-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Fibromyalgia" (unspecified if ongoing), notes: other medical history: Fibromyalgia; "history of anxiety/depression" (unspecified if ongoing), notes: other medical history: history of anxiety/depression. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (09Aug2023) Negative; (11Aug2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Covid Rebound after completing 5 day (10 dose) series. I began the treatment in the evening of 01Aug and finished the morning of 06Aug. I had negative tests on Wed. 09Aug and Friday 11Aug. Rebound symptoms started in the afternoon on Sunday 13Aug and included headache congestion, runny nose, sore throat, and fatigue. Paxlovid was taken as treatment from 01Aug2023-06Aug2023  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 01-APR-2013, the patient was inoculated with ZOSTAVAX in a pharmacy, as recommended for routine adult health maintenance and for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster or shingles. On or about 17-AUG-2016, the patient was treated by a Osteopathic physician for a blistering vesicular outbreak which was diagnosed as shingles. The patient was prescribed ZOVIRAX and NEURONTIN for management of her painful symptoms and excruciating pain. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient had suffered and would continue to suffer significant medical expenses, and pain and suffering, and other damages. At the time of this report, the outcome of the events was unknown. The causal assessment between the aforementioned events and vaccination with ZOSTAVAX was reported as related.
Blood clot in left leg; This is a spontaneous report from a contactable consumer (patient). A 47-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), on 25Jan2021 10:30 (lot: EL3302) as 1ST DOSE, SINGLE then on 17Feb2021 10:30 (lot: EL9264) as 2ND DOSE, SINGLE; both via an unspecified route of administration in left arm (at the age of 46-years-old) for covid-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient was not tested for COVID-19. Medical history included covid-19 (prior to vaccination, diagnosed with COVID) and no past drug event. The patient's concomitant medications were not reported. The reported event was blood clot in left leg on 18Apr2021 at 22:00. The event resulted in doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Treatment received for the adverse event was an unspecified medication. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
Patient reported extreme pain in his left arm - similar to when he had rotator cuff surgery. He was nauseous and incredibly cold (was in bed under the covers with his heavy coat on). His symptoms lasted for approximately 24 hours.
Per parents report in waiting room after vaccines pt had shaking of head/left hand for about 5 min.
rash from my left jaw to my groin that completely covered my torso front and back; Entire torso front and back tomy thighs turned completely red; This is a spontaneous report from a contactable nurse, the patient. A 51-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206) via an unspecified route of administration in the right arm on 04Mar2021 at 18:45hrs as a single dose for COVID-19 immunisation. Relevant medical history included asthma, ocular and skin rosacea. Concomitant medications included fexofenadine(ALLEGRA) taken for an unknown indication, albuterol inhaler(MANUFACTURER UNKNOWN) taken for asthma and multi-vitamin taken for an unknown indication. The patient had history of allergies to codeine, sulfa, z pak and vicodin allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient underwent a nasal swab test (PCR test) on 10Mar2021 for COVID-19 and the result found to be positive. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient experienced a rash two days after the vaccination on 06Mar2021. The patient reported that the rash extended from the left jaw to the groin region that completely covered his torso front and back. On an unspecified date in Mar2021, the patient reported that the rash faded away and the entire torso front and back to his thighs turned completely red as if the patient had a sunburn. The patient did not have any pain or itching. The adverse events resulted in a doctors or other healthcare professional visit. Therapeutic measures included intake of BENADRYL. The clinical outcome for the event rash was resolved on 08Mar2021 and the clinical outcome for the event entire torso front and back to thighs turned completely red was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Patient stated she felt tachycardic post vaccination [BP 176/95 mm/Hg & HR 78] enhanced observation vitals improved slightly [173/94 mm/Hg & 74 BPM.] Patient stated she felt better,
Pt had a breakthrough seizure 4 days after vaccination after not having a seizure  in over 6 years. Was also vomiting.
Injection site pain-minimal Tiredness- 3days, low energy Headache-severe for over 3 days Nausea- mild, 2 days Difficulty breathing- on two separate occasions after minimal activity
aches/soreness; headaches; Fever 102F; Chills; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (aches/soreness), HEADACHE (headaches), PYREXIA (Fever 102F) and CHILLS (Chills) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced MYALGIA (aches/soreness), HEADACHE (headaches), PYREXIA (Fever 102F) and CHILLS (Chills). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, MYALGIA (aches/soreness), HEADACHE (headaches), PYREXIA (Fever 102F) and CHILLS (Chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 31-Mar-2021, Body temperature: 102f (High) 102F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.
After receiving the fifth dose of Pfizer I started having brain fog, fatigue, chills and the next day I had all over body, joint, and muscle pain. I did not take the methocarbamol instead I used cannabis which helped, and I had zero pain and the other medication had a side effect of depression. The pain only lasted for about two days.
fever aches; fever; feel really bad; doc told me to get shingles vaccine,I had the 2 doses 4 yrs ago so I did not need this; This non-serious case was reported by a consumer and described the occurrence of pain in a 67-year-old male patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (The patient received 2 doses on an unknown date 4 years ago).   On 27-JUN-2023, the patient received the 3rd dose of Shingles vaccine. On 27-JUN-2023, less than a day after receiving Shingles vaccine, the patient experienced feeling bad (Verbatim: feel really bad) and off label use (Verbatim: doc told me to get shingles vaccine,I had the 2 doses 4 yrs ago so I did not need this). On an unknown date, the patient experienced pain (Verbatim: fever aches) and fever (Verbatim: fever). The outcome of the pain and fever were not reported and the outcome of the feeling bad was not resolved and the outcome of the off label use was unknown.   It was unknown if the reporter considered the pain, fever and feeling bad to be related to Shingles vaccine.     It was unknown if the company considered the pain, fever and feeling bad to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 30-JUN-2023 This report was via the online direct entry reporting system. This report was submitted by site: Public Reporting. The docter had told the patient  to get shingles vaccine so he got first dose, next day and the day of reporting the patient was feeling really bad.  His wife told him that he had the 2 doses 4 yrs ago so he did not need that. The symptoms were not treated. The reporter consent to follow up. The doctor had told to take Shinges vaccine even when the patient initially had completed 2 dose schedule of Shingles vaccine which led to off label use.
Sore , weak right arm first night. Took 400 mg Ibuprofen. Woke up next morning tired and slightly achy all over. Aches continued and worsened throughout the day.  Feeling very tired. Will be adding more Ibuprofen.
Patient felt "tired" after receiving vaccination while under observation. There was a small amount of blood from the injection site at the time of the injection. She drank a small amount of water (approx. 2 ounces) and then vomited a few moments later. She was pale and weak. She had previously had a similar reaction to a blood draw in the past. To be safe, 911 was called. EMTs arrived about 5 minutes later and examined the patient. Patient was examined - temp, BP and O2 were all normal. Patient was feeling better and was told she could leave or go to the hospital. The decision was left to the father who decided to take his daughter home. A follow up call was made at 4 PM and the patient was fine.